Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride

Journal of Clinical Pharmacology

Volumn 37, Issue 10, 1997, Pages 946-953

  Corey, Alfred ^a,e   Agnew, Jeffrey ^a   Bao, James ^a   Bryson, Philip ^b   Comer, Patrick ^c   Griffith, Susan ^d   Li, Junfang ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b Phase I Clinical Trials Unit   (United Kingdom)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d DUPONT COMPANY   (United States)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIMILIDE;

ADULT; AGE; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG URINE LEVEL; FEMALE; GENDER; HEART ARRHYTHMIA; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

EID: 0030776974     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04269.x     Document Type: Article

References (16)

1. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ Jr, Baskin EP, Lynch JI Jr, et al: Use-dependent effects of the Class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-271.
2. sK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). Eur J Pharmacol 1995;291:205-208.
3. KS in guinea pig cardiac myocytes. Biochem Biophys Res Comm 1994;202:265-270.
4. Restivo M, Hegazy M, El-Hamamy M, Yin H, Caref EB, Assadi MA, et al: Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model (abstract). Pacing Clin Electrophysiol 1996;19:664.
5. Qi X, Newman D, Dorian P: Class III effect of azimilide (NE-10064): prevention of reverse use-dependence in open-chest dogs (abstract). Pacing Clin Electrophysiol 1996;19:692.
6. Brandt MA, Maynard AE: NE-10064 exhibits Class III antiarrhythmic effects after intravenous or oral administration in conscious dogs (abstract). FASEB J 1994;8:A7.
7. Black SC, Butterfield JL, Lucchesi BR: Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-818.
8. Lavine SL, Prcevski P: Comparison of hemodynamic effects of 2 type III antiarrhythmic agents in dogs with chronic ischemic left ventricular dysfunction (abstract). J Invest Med 1996;44:211A.
9. Drexler AP, Al-Khalidi H, Maynard AE, Johnson NC, Jorgensen RL, Brooks RR, et al: Comparison of azimilide dihydrochloride (NE-10064) and selected class III antiarrhythmic agents in a rabbit model of proarrhythmia (abstract). FASEB J 1996;10:A33.
10. Kupfer A, Schmid B, Preisig R, Pfaff G: Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984;2:517-518.
11. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T: CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3:197-204.
12. Grant DM, Tang BK, Kalow W: A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-464.
13. Campbell ME, Speilberg SP, Kalow W: A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-165.
14. Kalow W, Tang BK: The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-514.
15. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR: Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-573.
16. Gibaldi M, Perrier D: Pharmacokinetics. New York: Marcel Dekker, Inc., 1982.